Biopharmaceutical company Erasca, Inc. (NASDAQ: ERAS) and Tango Therapeutics Inc. (NASDAQ: TNGX) announced a clinical collaboration to jointly conduct clinical evaluation of the combination therapy of ERAS-0015 and vopimetostat.

This collaboration aims to explore the potential of combining two innovative therapies, providing patients with more effective treatment options. Both parties plan to validate the synergistic effects of the combined approach through clinical research, with a focus on its safety and efficacy in specific indications. This partnership marks an important step forward for both companies in the field of tumor treatment and is expected to accelerate the development process of innovative therapies.